Rodrigues KF,Yong WTL,Bhuiyan MSA,Siddiquee S,Shah MD .2022 .Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review. Biology, 11 : 1308-12.
Collin-Histed T,Rosenberg A,Hopman N,Pacey J .2023 .Understanding patient and parent/caregiver perceptions on gene therapy in Gaucher disease: an international survey. Orphanet J Rare Dis, 18 : 5-9.
Roh J,Subramanian S,Weinreb NJ,Kartha RV .2022 .Gaucher disease - more than just a rare lipid storage disease. J Mol Med, 100 : 499-518.
Flotte TR,Cataltepe O,Puri A,Batista AR,Moser R,McKenna-Yasek D .2022 .AAV gene therapy for Tay-Sachs disease. Nat Med, 28 : 251-9.
Daykin EC,Ryan E,Sidransky E. .2021 .Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab, 132 : 49-58.
Hussein N,Henneman L,Kai J,Qureshi N. .2021 .Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, and Tay-Sachs disease. Cochrane Database Syst Rev, 10 : CD010849.
Marchetti M,Faggiano S,Mozzarelli A .2022 .Enzyme Replacement Therapy for Genetic Disorders Associated with Enzyme Deficiency. Curr Med Chem, 29 : 489-525.
Desnick RJ,Schuchman EH .2002 .Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet, 3 : 954-66.
Vairo F,Netto C,Dorneles A,Mittelstadt S,Wilke M,Doneda D .2013 .Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep, 11 : 1-6.
Phetthong T,Tim-Aroon T,Khongkraparn A,Noojarern S,Kuptanon C,Wichajarn K .2021 .Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients. Orphanet J Rare Dis, 16 : 519-23.
Bibi F,Ullah A,Bourinaris T,Efthymiou S,Kriouile Y,Sultan T .2021 .Tay-Sachs Disease: Two Novel Rare HEXA Mutations from Pakistan and Morocco. Klin Padiatr, 233 : 226-230.
Mistri M,Tamhankar PM,Sheth F,Sanghavi D,Kondurkar P,Patil S .2012 .Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India. PLoS One, 7(6) : e39122.
Hughes DA,Deegan P,Giraldo P,Göker-Alpan Ö,Lau H,Lukina E .2022 .Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J Clin Med, 11 : 5158-63.
Greuel A,Trezzi JP,Glaab E,Ruppert MC,Maier F,Jäger C .2020 .GBA variants in Parkinson's disease: clinical, metabolomic, and multimodal neuroimaging phenotypes. Movem Disord, 35 : 2201-10.
Lefter S,Mahony O,Sweeney O,Ryan B,AM B .2020 .Late-Onset Tay-Sachs Disease in an Irish Family. Mov Disord Clin Pract, 8 : 106-110.
Zhang X,Wu Y,Wang L,Wu Q,Liu Q,Li R .2023 .. Clinical Characteristics and GBA Gene Mutation Analysis of Gaucher Disease Type I. Clin Lab, 69 : 837-42.
Darling A,Irún P,Giraldo P,Armstrong J,Gort L,DíazConradi Á .2021 .Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinsonian features and levodopa responsiveness. Parkinsonism Relat Disord, 91 : 19-22.
Bilyalova A,Shagimardanova E,Bilyalov A,Zaripova M,Shigapova L,Gazizova G .2024 .Novel Hex A splice site mutations in a patient with late atypical onset Tay-Sachs disease: importance of combined NGS and biochemical analysis. Front Neurol, 15 : 1400989.
Istaiti M,Revel‐Vilk S,Becker‐Cohen M,Dinur T,Ramaswami U,Castillo‐Garcia D .2021 .Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. Am J Hematol, 96 : 545-51.
Park JH,Ko JM,Kim MS,Kim MJ,Seong MW,Yoo T .2021 .Novel HEXA variants in Korean children with TaySachs disease with regression of neurodevelopment from infancy. Mol Genet Genomic Med, 9 : e1677.
Dubiela P,Szymanska-Rozek P,Hasinski P,Lipinski P,Kleinotiene G,Giersz D,Short-Term Glucosphingosine D .2024 .lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy. Biomolecules, 14 : 842-7.
Sagaser KG,Malinowski J,Westerfield L,Proffitt J,Hicks MA,Toler TL .2023 .Expanded carrier screening for reproductive risk assessment: An evidence-based practice guideline from the National Society of Genetic Counselors. J Genet Couns, 32 : 540-557.
Lin Y,Zhao X,Liou B,Fannin V,Zhang W,Setchell KDR .2024 .Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease. Hum Mol Genet, 33 : 1771-88.
Eskes ECB,Beishuizen CRL,Corazolla EM,van Middelaar T,Brands MMMG,Dekker H .2022 .Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study. Orphanet J Rare Dis, 17 : 383-7.